There are various challenges associated with the development of CAR-T therapies for solid tumor cancers.
Brian Huber
Advertisement
Brian Huber is vice-president of Therapeutic Areas, Drug Development, and Consulting at ICON.
Articles by Brian Huber
The development of CAR-T therapies for solid tumor cancers presents a myriad of challenges.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Accepts BLA for Formycon and Zydus’ FYB206, the First Publicly Announced Keytruda Biosimilar Under Review
2
FDA Rare Disease Framework Initiative: What It Means for Drug and Biologic Development
3
BioNTech's BNT113 Misses PFS Goal in Head and Neck Cancer Trial
4
Gilead Taps Vir Biotechnology's PRO-XTEN Tech for Solid Tumors
5